tbuckley/cabot-search huggingface dataset:
The relevance of medical education to medical practice
Authors: H. Jason
Journal: JAMA (1970)

The observation that medical education is not particularly relevant to medical practice tends often to be dismissed as yet another dazzling glimpse of the obvious or as a description of an appropriate state of affairs, to be cherished rather than challenged. I will address myself to the inappropriateness of both these responses and examine the depth and the danger of the disparity between education and practice. Medical care in this country has come to be frequently referred to as a "nonsystem." For many of the same reasons, medical education must also be regarded as a nonsystem. In both spheres, current patterns have emerged from gradual, largely unplanned, evolution, rather than having been guided by either informed leadership or systematic research. Those largely anonymous individuals who have contributed to the shaping of our present programs of undergraduate medical education were equipped with generous quantities of good will and intuition which, regrettably,
Incorrect Academic Degree
Authors: William Figg
Journal: JAMA Oncology (2015)

grade tumor incidence is unlikely to translate to a reduction in prostate cancer mortality; on the other hand, such a reduction could reduce disease overdetection and overtreatment, a serious concern that led the US Preventive Services Task Force to recommend against PSA screening. 10The study by Azoulay et al 8 suggests that 5-ARI use is unlikely to increase prostate cancer mortality in men receiving them for BPH, reassuring those men on the symptom relief they may provide.
Comprehensive Neurology
Authors: Jonathan H. Pincus
Journal: JAMA (1992)

This textbook presents detailed and scholarly clinical descriptions of diseases and discussions of therapy. The emphasis is on the integration of basic neurobiologic information with the clinical setting. It attempts to provide a scientific understanding of the pathogenesis of neurological disorders and the rationale for their treatment. The book has many contributors, some among the finest academic neurologists in North America. Covered are conditions that do not appear in an ordinary textbook of neurology; there is, for example, a chapter on the neurological basis of psychiatric disorders. In it mood disorders are reviewed in relation to their genetic transmission. Unipolar and bipolar depression are distinguished. There is an extremely well-written and concise discussion of neurotransmitters and neuropeptides in mood disorders and of neuroendocrinology in relation to mood. The section continues in a comprehensive fashion to consider phobias, obsessive-compulsive disorders, eating disturbances, anxiety disorders, and schizophrenia. There is a very concise,
On Impetigo Contagiosa, or Porrigo
Authors: W. T. Fox
Journal: BMJ (1864)

with syphilitic iritis, having its usual characteristic marks-effusion of lymph, adhesion of the iris, dimness of vision, etc.He was ordered to have two grains of calomel and one-third of a grain of pow- lered opium every six hours.The effect of the mercury was soon visible on the vessels of the iris.Its natural colour was restored; the cornea became clear aoain; the red zone around it faded away; effused lymph was absorbed; and -vision again restored.He was now ordered three grains of iodide of potassium and an ounce of infusion of quassia three times a day, and was discharged cured in twenty-seven days.As syphilis, in some of its worst forms, comes under treatment from time to time in the wards of this hospital, the value of mercury as a remedy is fairly tested; and well-grounded opinions, founded on ex- perience, can be given in its favour.If those who argue against its use had an opportunity of studying syphilis in the wards of a lock hospital, or if attendance at those institutions formed part of the curriculum of the medical student, we should not have such divided opinions now-a-days upon the best mode of treating this disease.Men of great experience hold that mercury is a specific for syphilis; but they keep aloof from a controversy of mere words, when theory is more relied upon than facbs.The only remedy for this chaos of opinions on a question of such vital im- portance to the health, and, it may be justly acdded, the well-being of the people of this country, is the establishment of a special school of instruction for 'venereal diseases, the want of which must now be apparent to every thinking man in the profession.CASE OF :HIEATURIA.
Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
Authors: Daniel A. Goldstein, Bilal B. Ahmad, Qiushi Chen, Turgay Ayer, David H. Howard, Joseph Lipscomb, Bassel F. El-Rayes, Christopher Flowers
Journal: Journal of Clinical Oncology (2015)

6613 Background: Regorafenib was approved by the FDA in 2012 for the management of previously treated metastatic colorectal cancer (mCRC). It is now the standard of care in the third-line setting. Compared to placebo it improves median overall survival by 1.4 months but is associated with adverse effects and additional cost. The objective of this study was to examine the cost-effectiveness of regorafenib compared to best supportive care for patients receiving 3rd-line treatment for mCRC. Methods: We developed a Markov model to compare the cost and effectiveness of regorafenib compared to best supportive care in the 3rd-line treatment of mCRC based on randomized data from the CORRECT trial. Weibull models were fitted to the published overall and progression-free survival curves, and were used to extrapolate the cause-specific mortality and progression risks. Costs for administration and management of adverse events were based on Medicare reimbursement rates for hospital and physician services, and drug costs based on the Medicare average wholesale prices (all in 2014 US $). Health outcomes were measured in life years (LYs) and quality-adjusted life years (QALYs). Quality of life adjustments were calculated based on health utility values in the CORRECT trial and toxicity disutilities and durations were included for the most common toxicities: hand/foot syndrome, diarrhea, and hypertension. Model robustness was addressed by univariate and probabilistic sensitivity analyses (PSA). Results: In the model, regorafenib provided an additional 0.04 QALYs (0.13 LYs) at a cost of $39,391. The incremental cost-effectiveness ratio (ICER) was $897,411/QALY. In all one-way sensitivity analyses, the ICER of regorafenib was > $700,000/QALY. The ICER of regorafenib was greater than $200,000/QALY in > 99% of PSAs. Conclusions: This is the first US-based cost-effectiveness analysis of regorafenib in mCRC and our findings show that regorafenib provides minimal incremental benefit at high incremental cost per QALY. The ICER of regorafenib could be improved by use of an effective biomarker to select patients most likely to benefit, or by a lower price for payers.
Verbing and Nouning
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stories of a Country Doctor.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Postoperative gas gangrene
Authors: R. H. Maudsley
Journal: BMJ (1967)

SIR,-Your leading article "Postoperative Gas Gangrene " (14 October, p. 68) is a timely reminder of the unexpected and, fortunately, unusual risk run by the patient after surgery.This risk exists despite exhaustive efforts to control the environmental and personal sources of Clostridium welchii.I believe clostridial cellulitis and myositis occur more commonly than is realized.Since the opening of a small hyperbaric oxygen unit three years ago 16 cases of postoperative and post-traumatic gas gangrene have been admitted from a relatively small population.Answers from a group of ortho- paedic surgeons indicated that more than 50 cases had occurred in a population of three million in five years.You state that gas gangrene is a rare and terrifying disease, as indeed many diseases have been prior to methods of control.Gas gangrene, however, has yielded over the last 10 years to a most effective form of treatment, hyperbaric oxygen, first reported by Boerema.' Van Zyl,' reporting on 200
SECOND THOUGHTS
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>Man—An Adaptive Mechanism</i>. By George W. Crile, F. A. C. S., Professor of Surgery, School of Medicine, Western Reserve University; Visiting Surgeon to the Lakeside Hospital, Cleveland. Edited by Annette Austin, A. B. Price $2.50. (<i>New York: The Macmillan Company,1916</i>.)
Authors: W. R. D.
Journal: American Journal of Psychiatry (1916)
Cancer Patient
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Carcinogenicity of Lipid-Lowering Drugs
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Borderline substances.
Authors: D G Mayne
Journal: BMJ (1977)

Developmental screening of preschool children SIR,-I was intrigued by the article by Dr D J G Bain on "Methods used by general practitioners in developmental screening of preschool children" (6 August, p 363) in its revelation of such free-for-all methodology."Examination forms," "visual charts," "alter- native screening forms"-you think of it, the examining doctors choose it.Why are they
Utility of FDG-PET imaging in predicting the aggressiveness and histopathology of lymphoma
Authors: S. R. Chandana, K. Berger, G. Krishnan
Journal: Journal of Clinical Oncology (2008)

19507 Background: F(18)-fluorodeoxyglucose positron emission tomography ((18) F-FDG PET) is widely used in the staging and restaging of Non-Hodgkin’s lymphoma (NHL) and Hodgkin’s Disease (HD). The primary objective of our study is to understand the clinical utility of standard uptake value (SUV), in determining the aggressiveness of NHL and HD. Secondary objective of this study is to assess whether SUV can differentiate among histopathological subtypes. Methods: All FDG PET studies done in patients with NHL and HD between Jan 2004 and Dec 2007 were evaluated retrospectively. Inclusion criteria include PET before any therapy or on relapse of the disease; histopathology review; no diagnosis of diabetes mellitus or other types of cancer and time interval of < 60 days between PET and histopathology. PET scans were reviewed and the maximum standard uptake value (SUV (max)) at the site of the biopsy was measured and compared with histopathological diagnoses. Results: One hundred and forty three patients (mean age 56.2 ± 17.2 years, 83 males, 60 females, 25 patients with HD, 62 with aggressive NHL 56 with indolent NHL were included. The distribution of various histopathologies was shown in the table. The mean SUV (max) were statistically different between aggressive and indolent NHL (13.5 ± 7.5 vs. 4.2 ± 2.3, p < 0.001). The mean SUV (max) were not statistically different between DLBCL, HD and T-cell Lymphoma. Mean SUV (max) of MALT Lymphoma were similar to FL-I and those of mantle cell lymphomas were close to FL-II. Conclusions: Our ongoing study suggests that FDG-PET, not only can distinguish aggressive from indolent lymphomas, but also different hitopathological varieties of lymphoma. This information may be helpful if there is discordance between biopsy and clinical behavior. An increase in the sample size could differentiate between different histopathological subgroups of lymphomas. Mean SUV values of different histopathological types of lymphoma Histopathology N SUV(mean ±SD) HD 25 11.5 ± 5.7 DLBCL and FL-II 56 13.2 ± 7.5 T-Cell Lymphoma 6 16.2 ± 6.7 FL-II 19 5.8 ± 2.3 FL-I 27 3.0 ± 1.2 Mantle Cell 7 5.0 ± 2.8 MALT Lymphoma 3 2.5 ± 1.4 DLBCL –Diffuse large B-cell lymphoma, FL-Follicular lymphoma, MALT –Mucosa associated lymphoid tissue No significant financial relationships to disclose.
Editorial Board
Authors: Treasa Creavin, Sara Cullinan, Eleanor Carr, Suado Assistant, Simon Bradbrook, Lara Crow, Mat Mccutcheon, Philip Patenall, Neill Sharp, & Ceo, Lynne Herndon, Emilie Marcus, Fabio Iannelli, Graziano Pesole, Paolo Sordino, Carmela Gissi, Ana Gutiérrez-Preciado, Charles Yanofsky, Enrique Merino, Xin Li, Jing Liang, Haijing Yu, Bing Su, Chunjie Xiao, Yongfeng Shang, Wen Wang, Sarah Whitcomb, Amrita Basu, C David, Emily Bernstein, Xiaoqi Feng, Hugh Dickinson, Alistair Darby, Nam-Huyk Cho, Hans-Henrik Fuxelius, Joakim Westberg, Siv Andersson Helitrons, Vladimir Kapitonov, Jerzy Jurka, Lori Handley, Andrea Manica, Jérôme Goudet, François Balloux, Timothy Hore, Robert Rapkins, Jennifer Graves, Laura Smith, Gregory Otterson, Christoph Plass, Sophie Breton, Hélène Doucet Beaupré, Donald Stewart, Walter Hoeh, Pierre Blier
Journal: Trends in Genetics (2007)
Gene Therapy Setback
Authors: Joan Stephenson
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE NOT-SO-HEALTHY OUTDOORS
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Modification of Odén Bandage.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Benign intrathoracic lesions mimicking recurrent cancer
Authors: E. A. Sickles
Journal: JAMA (1973)

Three of 15 cancer patients with suspected intrathoracic tumor recurrence were found on biopsy to have only benign mass lesions. These cases emphasize that medical work-up, short of biopsy, is often inadequate in the evaluation of intrathoracic masses, and that a history of neoplasm is not sufficient cause to abandon tissue diagnosis before proceeding to therapy.